As the demand for COVID vaccines decreases worldwide, Moderna is planning to release a RSV vaccine, pending U.S. approval.
Moderna posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales ...
The company expects the first batches of the COVID-19 vaccine, JNJ-78436735 ... The average price target represents a 14.23% increase from the last price of $146.07. All those seven equity ...
Moderna will chart its post-Covid future Wednesday during its fifth annual "Vaccines Day," an investor ... need that Moderna ...
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday. Moderna CEO ...
Many people vaccinated for COVID-19 also received other vaccines, such as influenza, simultaneously," Isham added in a statement. In 2022, Pfizer and Moderna had their first-generation mRNA COVID ...
A guide to the coronavirus vaccination rollout and what you need to know about the authorized vaccines Some 63.8% of Americans have received both doses of the two-shot Pfizer-BioNTech and Moderna ...
Authors focused their research on those who received the COVID vaccine from Pfizer or Moderna and died within 100 days of receiving their shots. Only 40 deaths occurred in that window. Of the 40 ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
opens new tab copied its COVID-19 vaccine technology will be put on hold while the U.S. Patent Office determines whether two of the three Moderna patents at issue are valid, a Massachusetts ...